See more : HDHMS (443060.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Vera Therapeutics, Inc. (VERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Freightways Limited (FRE.NZ) Income Statement Analysis – Financial Results
- Maruwa Co., Ltd. (MAW.L) Income Statement Analysis – Financial Results
- ICC Holdings, Inc. (ICCH) Income Statement Analysis – Financial Results
- NextMart, Inc. (NXMR) Income Statement Analysis – Financial Results
- Consolidated Woodjam Copper Corp. (WCC.V) Income Statement Analysis – Financial Results
Vera Therapeutics, Inc. (VERA)
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| Gross Profit | 1.86M | 846.00K | -176.00K | -251.00K | -509.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 78.23M | 68.99M | 22.48M | 45.21M | 7.29M |
| General & Administrative | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Other Expenses | 0.00 | 1.85M | 1.79M | -1.08M | 0.00 |
| Operating Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Cost & Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Interest Income | 4.19M | 1.75M | 15.00K | 8.00K | 159.00K |
| Interest Expense | 0.00 | 992.00K | 20.00K | 166.00K | 51.00K |
| Depreciation & Amortization | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| EBITDA | -102.01M | -90.90M | -34.23M | -53.00M | -11.19M |
| EBITDA Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -102.01M | -90.90M | -34.40M | -52.24M | -11.96M |
| Operating Income Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.02M | 1.85M | 1.79M | -1.17M | 108.00K |
| Income Before Tax | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Income Before Tax Ratio | -5,155.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Net Income Ratio | -5,155.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| EPS Diluted | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| Weighted Avg Shares Out | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
| Weighted Avg Shares Out (Dil) | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
Vera Therapeutics, Inc. topline 36-week data from the phase 3 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected Q2 of 2025. 96-week data from the phase 2 ORIGIN study, using Atacicept for the treatment of...
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
BRISBANE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that long-term results from the ORIGIN Phase...
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
BRISBANE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced expansion of its development pipeline for its...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on September 5, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 21,750 shares of Class A common...
Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says
Adobe shares are up 31% over the past three months, having rallied after a strong quarterly earnings report that highlighted strong demand for the software developer's AI products.
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on August 6, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 33,000 shares of Class A common...
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 160,000...
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 4, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 31,250 shares...
Source: https://incomestatements.info
Category: Stock Reports